Drug Profile


Alternative Names: Januvia/Zocor; Juvicor; Juvisync; MK-0431D; MK-431D; Tesozor; Xelezor; Zocor/Januvia

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Antihyperlipidaemics; Naphthalenes; Pyrazines; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 01 Aug 2017 Discontinued - Phase-III for Type-2 diabetes mellitus in Vietnam, Italy, Poland, Hungary, Latvia and Lithuania (PO), because not listed on Merck pipeline of August 2017
  • 30 Apr 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in Vietnam (PO)
  • 01 Nov 2013 Merck terminates the phase III trial in Type-2 diabetes mellitus in USA, Lithuania, Latvia, Hungary, Poland and Italy for business reasons (EudraCT2012-001868-29; NCT01678820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top